Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Sakai · SciRah

Researcher profile · Semantic Scholar

D. Sakai

Share profile

D. Sakai — researcher profile on SciRah

h-index: 29
Works: 214
Citations: 4,394

Most-cited papers

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
K. Shitara, Y. Bang, S. Iwasa, N. Sugimoto +12 more
2020New England Journal of Medicine1,047 citations Open access
Semantic Scholar
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
C. Fuchs, K. Shitara, M. Di Bartolomeo, S. Lonardi +140 more
2019The Lancet Oncology259 citations Open access
Semantic Scholar
Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)
T. Ioka, M. Kanai, Shogo Kobayashi, D. Sakai +17 more
2022Journal of hepato-biliary-pancreatic sciences201 citations Open access
Semantic Scholar
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial
K. Shitara, Yung-Jue Bang, S. Iwasa, N. Sugimoto +17 more
2024Nature Medicine112 citations Open access
Semantic Scholar
Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
K. Yamaguchi, Y. Bang, S. Iwasa, N. Sugimoto +14 more
2022Journal of Clinical Oncology110 citations Open access
Semantic Scholar
A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
Shogo Kobayashi, H. Nagano, A. Tomokuni, K. Gotoh +13 more
2019Annals of Surgery62 citations
Semantic Scholar
The mitochondrial one-carbon metabolic pathway is associated with patient survival in pancreatic cancer.
Kozo Noguchi, M. Konno, J. Koseki, N. Nishida +13 more
2018Oncology Letters56 citations Open access
Semantic Scholar
A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma
H. Eguchi, Y. Takeda, Hidenori Takahashi, S. Nakahira +7 more
2019Annals of Surgical Oncology49 citations
Semantic Scholar
1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
K. Yamaguchi, Y. Bang, S. Iwasa, N. Sugimoto +12 more
202046 citations Open access
Semantic Scholar
Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer
T. Denda, D. Sakai, T. Hamaguchi, N. Sugimoto +19 more
2019Cancer Science34 citations Open access
Semantic Scholar
Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer
Takaomi Hagi, T. Makino, M. Yamasaki, Koji Tanaka +7 more
2019Annals of Surgical Oncology32 citations
Semantic Scholar
Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial
M. Yagisawa, H. Taniguchi, T. Satoh, S. Kadowaki +17 more
2024Journal of Clinical Oncology31 citations Open access
Semantic Scholar
Phase IIb study of pembrolizumab combined with S‐1 + oxaliplatin or S‐1 + cisplatin as first‐line chemotherapy for gastric cancer
K. Yamaguchi, K. Minashi, D. Sakai, T. Nishina +19 more
2022Cancer Science27 citations Open access
Semantic Scholar
Clinical Utility of Next-Generation Sequencing-Based Panel Testing under the Universal Health-Care System in Japan: A Retrospective Analysis at a Single University Hospital
C. Inagaki, D. Maeda, K. Hatake, Yuki Sato +5 more
2021Cancers22 citations Open access
Semantic Scholar
Comparison of S-1–cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials
H. Kawakami, K. Fujitani, J. Matsuyama, Y. Akamaru +12 more
2020International Journal of Clinical Oncology20 citations
Semantic Scholar
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
D. Sakai, H. Taniguchi, N. Sugimoto, T. Tamura +35 more
2020European Journal of Cancer19 citations
Semantic Scholar
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
K. Yamaguchi, Y. Bang, S. Iwasa, N. Sugimoto +12 more
202117 citations
Semantic Scholar
Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).
H. Taniguchi, M. Yagisawa, T. Satoh, S. Kadowaki +16 more
2023Journal of Clinical Oncology16 citations Open access
Semantic Scholar
Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant S‐1 chemotherapy after gastrectomy: A multicenter, open‐label, single‐arm, prospective phase II study (OGSG1108)
H. Imamura, J. Matsuyama, K. Nishikawa, S. Endo +13 more
2021Annals of Gastroenterological Surgery16 citations Open access
Semantic Scholar
Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
Akie Kimura Yoshikawa, K. Yamaguchi, K. Muro, A. Takashima +12 more
2022Journal for ImmunoTherapy of Cancer14 citations Open access
Semantic Scholar
Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
M. Tsujie, T. Iwai, S. Kubo, T. Ura +14 more
2021Japanese Journal of Clinical Oncology14 citations Open access
Semantic Scholar
Impact of sarcopenia in patients with advanced or recurrent colorectal cancer treated with regorafenib
Y. Murachi, D. Sakai, J. Koseki, C. Inagaki +3 more
2020International Journal of Clinical Oncology14 citations
Semantic Scholar
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study
T. Moriwaki, S. Fukuoka, T. Masuishi, A. Takashima +21 more
2019International Journal of Clinical Oncology14 citations
Semantic Scholar
Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3)
Y. Kurokawa, J. Matsuyama, K. Nishikawa, A. Takeno +9 more
2020Gastric Cancer13 citations Open access
Semantic Scholar
A Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).
T. Terazawa, J. Matsuyama, M. Goto, R. Kawabata +15 more
2019The Oncologist13 citations Open access
Semantic Scholar
Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study
D. Sakai, T. Omori, S. Fumita, J. Fujita +18 more
2022International Journal of Clinical Oncology12 citations Open access
Semantic Scholar
Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study
S. Endo, T. Terazawa, M. Goto, R. Tanaka +8 more
2022BMC Cancer11 citations Open access
Semantic Scholar
O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma
K. Shitara, Y. Bang, S. Iwasa, N. Sugimoto +15 more
2021Annals of Oncology11 citations Open access
Semantic Scholar
Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild-type colorectal cancer: OGSG 1602.
K. Ohta, Takeshi Kato, M. Goto, T. Terazawa +16 more
202011 citations
Semantic Scholar
A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma
A. Ooki, T. Satoh, K. Muro, A. Takashima +12 more
2022Scientific Reports10 citations Open access
Semantic Scholar
Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
H. Taniguchi, T. Yamanaka, D. Sakai, K. Muro +7 more
2020Cancers10 citations Open access
Semantic Scholar
A Phase I Study of Neoadjuvant Capecitabine, Oxaliplatin, and Irinotecan (XELOXIRI) in Patients with Locally Advanced Rectal Cancer
T. Kudo, I. Takemasa, Tsuyoshi Hata, D. Sakai +9 more
2019Oncology10 citations
Semantic Scholar
Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202
S. Endo, Y. Kurokawa, M. Gamoh, Y. Kimura +11 more
2019Anticancer Research9 citations Open access
Semantic Scholar
Gallbladder cancer harboring ERBB2 mutation on the primary and metastatic site: A case report
C. Inagaki, D. Maeda, Akie Kimura, T. Otsuru +7 more
2019World Journal of Gastrointestinal Oncology8 citations Open access
Semantic Scholar
Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan
K. Kunimasa, N. Sugimoto, Tomoyuki Yamasaki, Yoji Kukita +15 more
2024Cancer Medicine7 citations Open access
Semantic Scholar
The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy
C. Inagaki, H. Kawakami, D. Maeda, D. Sakai +7 more
2023Scientific Reports7 citations Open access
Semantic Scholar
Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials
Y. Kimura, H. Kawakami, S. Tamura, K. Fujitani +9 more
2023Gastric Cancer6 citations Open access
Semantic Scholar
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
H. Nakajima, S. Fukuoka, T. Masuishi, A. Takashima +23 more
2021Frontiers in Oncology6 citations Open access
Semantic Scholar
A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy
M. Ueno, C. Morizane, M. Furukawa, D. Sakai +19 more
2021Cancer Medicine6 citations Open access
Semantic Scholar
Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)
K. Chida, D. Kotani, T. Moriwaki, S. Fukuoka +24 more
2021Frontiers in Oncology6 citations Open access
Semantic Scholar
A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302)
S. Tamura, H. Taniguchi, K. Nishikawa, H. Imamura +13 more
2020International Journal of Clinical Oncology6 citations Open access
Semantic Scholar
Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study
K. Shitara, K. Yamaguchi, K. Muro, H. Yasui +9 more
2023International Journal of Clinical Oncology5 citations Open access
Semantic Scholar
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study)
M. Kotaka, S. Iwamoto, H. Satake, D. Sakai +14 more
2020International Journal of Clinical Oncology5 citations
Semantic Scholar
Combination Therapy With S-1, Oxaliplatin and Leucovorin in Patients With Advanced Esophageal Squamous Cell Carcinoma
N. Nishida, Makoto Yamsaki, Kazuki Odagiri, K. Yamashita +8 more
2019In Vivo5 citations Open access
Semantic Scholar
Nivolumab-induced interstitial lung disease in a patient with gastric cancer
Akie Kimura, D. Sakai, T. Kudo, N. Nishida +12 more
2019Oxford Medical Case Reports5 citations Open access
Semantic Scholar
Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B
Y. Kawamoto, C. Morizane, Y. Komatsu, S. Kondo +13 more
2024Future Oncology4 citations Open access
Semantic Scholar
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
K. Yamaguchi, Y. Bang, S. Iwasa, N. Sugimoto +12 more
2022Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naïve Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer: OGSG 1602.
T. Terazawa, Takeshi Kato, M. Goto, K. Ohta +16 more
2020The Oncologist4 citations Open access
Semantic Scholar
O-11 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)
K. Yamaguchi, Y. Bang, S. Iwasa, N. Sugimoto +12 more
20204 citations Open access
Semantic Scholar
[Successful R0 Resection of Hilar Cholangiocarcinoma by Extrahepatic Bile Duct Resection Due to Accompanying Liver Dysfunction after Neoadjuvant Gemcitabine/Cisplatin/S-1 Combination Chemotherapy-A Case Report].
M. Higashiguchi, Daisaku Yamada, H. Akita, H. Eguchi +10 more
2019Gan to kagaku ryoho. Cancer & chemotherapy4 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Satoh×25
Invite
T. Satoh — researcher profile on SciRah
H. Kawakami×19
Invite
H. Kawakami — researcher profile on SciRah
N. Sugimoto×17
Invite
N. Sugimoto — researcher profile on SciRah
K. Yamaguchi×13
Invite
K. Yamaguchi — researcher profile on SciRah

×13

Invite

Y. Kurokawa — researcher profile on SciRah

Invite

K. Shitara — researcher profile on SciRah

Invite

Y. Doki — researcher profile on SciRah

T. Shimokawa×10

Invite

T. Shimokawa — researcher profile on SciRah

Invite

M. Sugihara — researcher profile on SciRah

Invite

S. Iwasa — researcher profile on SciRah

Invite

H. Yabusaki — researcher profile on SciRah

Invite

K. Saito — researcher profile on SciRah